CERT Certara Inc.

Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Date	Price Target	Rating	Analyst
5/8/2025	$14.00	Equal Weight → Overweight	Barclays
2/27/2025	$16.00	Buy	TD Cowen
9/27/2024	$16.00	Neutral → Buy	UBS
4/10/2024	$23.00	Sector Weight → Overweight	KeyBanc Capital Markets
4/4/2024		Mkt Perform	JMP Securities
2/26/2024	$19.00	Market Perform	Leerink Partners
12/7/2023	$17.00	Neutral	UBS
12/5/2023		Sector Weight	KeyBanc Capital Markets
8/22/2023	$24.50 → $17.00	Buy → Hold	Jefferies
8/10/2023		Outperform → Mkt Perform	William Blair

Certara Inc.

Recent Analyst Ratings for Certara Inc.

Certara Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Human Resources Officer Anhalt Rona converted options into 7,146 shares and covered exercise/tax liability with 1,965 shares (SEC Form 4)

SVP and General Counsel Corcoran Daniel converted options into 7,940 shares, covered exercise/tax liability with 6,607 shares and converted options into 14,888 units of Comon Stock (SEC Form 4)

Director Walsh Matthew M converted options into 11,928 shares, increasing direct ownership by 6% to 197,559 units (SEC Form 4)

Director Reynders John V W converted options into 10,709 shares (SEC Form 4)

Director Killefer Nancy converted options into 11,928 shares, increasing direct ownership by 49% to 36,089 units (SEC Form 4)

Director Crane Rosemary A converted options into 11,928 shares, increasing direct ownership by 66% to 29,915 units (SEC Form 4)

Director Collins Cynthia converted options into 11,928 shares, increasing direct ownership by 49% to 36,089 units (SEC Form 4)

Chairman Cashman James E Iii converted options into 11,928 shares, increasing direct ownership by 3% to 468,440 units (SEC Form 4)

Chairman Broshy Eran converted options into 11,928 shares, increasing direct ownership by 52% to 34,951 units (SEC Form 4)

SEC Form 4 filed by Chief Human Resources Officer Anhalt Rona